Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Лечение гипергликемии при сахарном диабете 2 типа, 2018 г.: консенсусный доклад Американской диабетологической ассоциации (ADA) и Европейской ассоциации по изучению диабета (EASD)
2018-10-05
SCID: 54.1/h3pzbwc6
Discuss with AI
Diabetes self-management educationGLP-1 receptor agonistsHyperglycemia managementSGLT2 inhibitorsType 2 diabetes
Figures from the paper
Abstract (AI)
The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the prior position statements, published in 2012 and 2015, on the management of type 2 diabetes in adults. A systematic evaluation of the literature since 2014 informed new recommendations. These include additional focus on lifestyle management and diabetes self-management education and support. For those with obesity, efforts targeting weight loss, including lifestyle, medication, and surgical interventions, are recommended. With regards to medication management, for patients with clinical cardiovascular disease, a sodium-glucose cotransporter 2 (SGLT2) inhibitor or a glucagon-like peptide 1 (GLP-1) receptor agonist with proven cardiovascular benefit is recommended. For patients with chronic kidney disease or clinical heart failure and atherosclerotic cardiovascular disease, an SGLT2 inhibitor with proven benefit is recommended. GLP-1 receptor agonists are generally recommended as the first injectable medication.
Key Findings
1
An SGLT2 inhibitor with demonstrated benefit is recommended for patients with chronic kidney disease or clinical heart failure and atherosclerotic cardiovascular disease.
2
For people with obesity, recommended weight-loss strategies include lifestyle interventions, medications, and metabolic surgery.
3
GLP-1 receptor agonists are generally recommended as the preferred first injectable medication.
4
Patients with clinical cardiovascular disease should receive an SGLT2 inhibitor or GLP-1 receptor agonist with proven cardiovascular benefit.
5
The ADA and EASD updated adult type 2 diabetes management recommendations using a systematic evaluation of literature published since 2014.
6
The consensus places greater emphasis on lifestyle management and diabetes self-management education and support.
7
Агонисты рецептора GLP-1 в целом рекомендуются как предпочтительные препараты для первой инъекционной терапии.
8
Для взрослых с сахарным диабетом 2 типа ADA и EASD обновили рекомендации на основе систематической оценки литературы, опубликованной с 2014 года.
9
Консенсус уделяет больше внимания коррекции образа жизни и обучению и поддержке самостоятельного управления диабетом.
10
Людям с ожирением рекомендуются стратегии снижения массы тела, включая изменение образа жизни, лекарственную терапию и метаболическую хирургию.
11
Пациентам с клинически выраженным сердечно-сосудистым заболеванием рекомендуется ингибитор SGLT2 или агонист рецептора GLP-1 с доказанной сердечно-сосудистой пользой.
12
Пациентам с хронической болезнью почек или клинической сердечной недостаточностью и атеросклеротическим сердечно-сосудистым заболеванием рекомендуется ингибитор SGLT2 с доказанной пользой.
Research Object
Management of hyperglycemia in type 2 diabetes (clinical treatment strategies for glycemic control and related comorbidity risk)
Research Subject
Evidence-based treatment recommendations, including lifestyle and self-management support, weight-loss interventions, and selection of glucose-lowering medications according to obesity, cardiovascular disease, chronic kidney disease, and heart failure
Publication Details
Publication Date
2018-10-05
Journal
Publisher
ISSN
Cited by
3575
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai6
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes2015
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes2017
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes2016
Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes2008
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes2016
Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes2014
Cited by3
2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association2021
Prevention of Type 2 Diabetes by Lifestyle Changes: A Systematic Review and Meta-Analysis2019
5. Facilitating Behavior Change and Well-being to Improve Health Outcomes:Standards of Medical Care in Diabetes—20222021